Source-grounded facts extracted from AtriCure, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
AtriCure, Inc. reported the first quarter ended March 31, 2026 results: revenue $141.2 million, net income $0.1 million, EPS $0.00.
“First Quarter 2026 worldwide revenue of $141.2 million, an increase of 14.3% year over year • First Quarter 2026 profitability improved, with net income of $0.1 million and adjusted EBITDA of $17.1 million”
AtriCure, Inc. reported first quarter ended March 31, 2026 results: revenue $141.2 million, net income $0.1 million, EPS breakeven at $0.00.
“or document. --- EX-99.1 (EX-99.1) --- For immediate release May 5, 2026 AtriCure Reports First Quarter 2026 Financial Results • First Quarter 2026 worldwide revenue of $141.2 million, an increase of 14.3% year over year • First Quarter 2026 profitability improved, with net income of $0.1 million and adjusted EBITDA of $17.1 million • U.S. revenue growth”
AtriCure, Inc. amended First Amendment to Credit Agreement with JPMorgan Chase Bank, N.A., as administrative agent, bookrunner and lead arranger, and the lenders party thereto (effective 2026-01-09).
“On January 9, 2026 (the “ Closing Date ”), AtriCure, Inc. (the “ Company ”) and its wholly owned subsidiary, AtriCure, LLC (together with the Company, the “ Borrowers ”), entered into a First Amendment (“ First Amendment ”) to Credit Agreement (as amended, the “ Credit Agreement ”) among the Borrowers, JPMorgan Chase Bank, N.A., as administrative agent (in such capacity, the “ Administrative Agent ”), JPMorgan Chase Bank, N.A., as bookrunner and lead arranger (“ JPMCB ”), and the lenders party thereto (“ Lenders ”).”
AtriCure, Inc.: Amendment to Second Amended and Restated Certificate of Incorporation to limit liability of certain officers (effective 2024-05-13).
“At the Annual Meeting, the stockholders of the Company approved an amendment (the “Amendment”) to the Company’s Second Amended and Restated Certificate of Incorporation to limit the liability of certain officers of the Company as permitted by the Delaware General Corporation Law. The Amendment became effective immediately upon the filing of a certificate of amendment setting forth the same with the Secretary of State of the State of Delaware on May 13, 2024.”
AtriCure, Inc. shareholders approved Approval of an amendment to the Company’s Second Amended and Restated Certificate of Incorporation to limit the liability of certain officers of the Company at the 2024-05-14 meeting.
“5. The stockholders approved the amendment to the Company’s Second Amended and Restated Certificate of Incorporation to limit the liability of certain officers of the Company. For: 37,737,714 Against: 4,398,481 Abstain: 78,142 Broker Non-Votes: 2,575,972”
AtriCure, Inc. shareholders approved Approval of an amendment to the AtriCure, Inc. 2023 Stock Incentive Plan to increase the number of shares of common stock authorized for issuance thereunder by 1,800,000 at the 2024-05-14 meeting.
“4. The stockholders approved the amendment to the AtriCure, Inc. 2023 Stock Incentive Plan to increase the number of shares of common stock authorized for issuance thereunder by 1,800,000. For: 40,884,921 Against: 1,252,515 Abstain: 76,901 Broker Non-Votes: 2,575,972”
AtriCure, Inc. shareholders approved Advisory vote on the compensation of the Company’s named executive officers as disclosed in the proxy statement at the 2024-05-14 meeting.
“3. The stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the proxy statement. For: 35,640,238 Against: 6,475,860 Abstain: 98,239 Broker Non-Votes: 2,575,972”
AtriCure, Inc. shareholders approved Ratify the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024 at the 2024-05-14 meeting.
“2. The stockholders approved the proposal to ratify the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024. For: 44,157,266 Against: 550,817 Abstain: 82,226”
AtriCure, Inc. shareholders approved Election of Maggie Yuen as director at the 2024-05-14 meeting.
“Each nominee for director was duty elected to serve one-year terms expiring at the 2025 Annual Meeting of Stockholders and until their successors have been duly elected and qualified. Director Nominees For Against Abstain Broker Non-Votes Michael H. Carrel 41,522,276 637,966 54,095 2,575,972 Regina E. Groves 41,564,382 594,967 54,988 2,575,972 B. Kristine Johnson 40,322,588 1,836,733 55,016 2,575,972 Shlomo Nachman 41,948,710 209,253 56,374 2,575,972 Karen N. Prange 40,301,694 1,857,627 55,016 2,575,972 Deborah H. Telman 40,249,839 1,909,510 54,988 2,575,972 Sven A. Wehrwein 40,080,389 2,078,609 55,339 2,575,972 Robert S. White 40,893,534 1,265,449 55,354 2,575,972 Maggie Yuen 41,565,558 593,708 55,071 2,575,972”
AtriCure, Inc. shareholders approved Election of Robert S. White as director at the 2024-05-14 meeting.
“Each nominee for director was duty elected to serve one-year terms expiring at the 2025 Annual Meeting of Stockholders and until their successors have been duly elected and qualified. Director Nominees For Against Abstain Broker Non-Votes Michael H. Carrel 41,522,276 637,966 54,095 2,575,972 Regina E. Groves 41,564,382 594,967 54,988 2,575,972 B. Kristine Johnson 40,322,588 1,836,733 55,016 2,575,972 Shlomo Nachman 41,948,710 209,253 56,374 2,575,972 Karen N. Prange 40,301,694 1,857,627 55,016 2,575,972 Deborah H. Telman 40,249,839 1,909,510 54,988 2,575,972 Sven A. Wehrwein 40,080,389 2,078,609 55,339 2,575,972 Robert S. White 40,893,534 1,265,449 55,354 2,575,972 Maggie Yuen 41,565,558 593,708 55,071 2,575,972”
AtriCure, Inc. shareholders approved Election of Sven A. Wehrwein as director at the 2024-05-14 meeting.
“Each nominee for director was duty elected to serve one-year terms expiring at the 2025 Annual Meeting of Stockholders and until their successors have been duly elected and qualified. Director Nominees For Against Abstain Broker Non-Votes Michael H. Carrel 41,522,276 637,966 54,095 2,575,972 Regina E. Groves 41,564,382 594,967 54,988 2,575,972 B. Kristine Johnson 40,322,588 1,836,733 55,016 2,575,972 Shlomo Nachman 41,948,710 209,253 56,374 2,575,972 Karen N. Prange 40,301,694 1,857,627 55,016 2,575,972 Deborah H. Telman 40,249,839 1,909,510 54,988 2,575,972 Sven A. Wehrwein 40,080,389 2,078,609 55,339 2,575,972 Robert S. White 40,893,534 1,265,449 55,354 2,575,972 Maggie Yuen 41,565,558 593,708 55,071 2,575,972”
AtriCure, Inc. shareholders approved Election of Deborah H. Telman as director at the 2024-05-14 meeting.
“Each nominee for director was duty elected to serve one-year terms expiring at the 2025 Annual Meeting of Stockholders and until their successors have been duly elected and qualified. Director Nominees For Against Abstain Broker Non-Votes Michael H. Carrel 41,522,276 637,966 54,095 2,575,972 Regina E. Groves 41,564,382 594,967 54,988 2,575,972 B. Kristine Johnson 40,322,588 1,836,733 55,016 2,575,972 Shlomo Nachman 41,948,710 209,253 56,374 2,575,972 Karen N. Prange 40,301,694 1,857,627 55,016 2,575,972 Deborah H. Telman 40,249,839 1,909,510 54,988 2,575,972 Sven A. Wehrwein 40,080,389 2,078,609 55,339 2,575,972 Robert S. White 40,893,534 1,265,449 55,354 2,575,972 Maggie Yuen 41,565,558 593,708 55,071 2,575,972”
AtriCure, Inc. shareholders approved Election of Karen N. Prange as director at the 2024-05-14 meeting.
“Each nominee for director was duty elected to serve one-year terms expiring at the 2025 Annual Meeting of Stockholders and until their successors have been duly elected and qualified. Director Nominees For Against Abstain Broker Non-Votes Michael H. Carrel 41,522,276 637,966 54,095 2,575,972 Regina E. Groves 41,564,382 594,967 54,988 2,575,972 B. Kristine Johnson 40,322,588 1,836,733 55,016 2,575,972 Shlomo Nachman 41,948,710 209,253 56,374 2,575,972 Karen N. Prange 40,301,694 1,857,627 55,016 2,575,972 Deborah H. Telman 40,249,839 1,909,510 54,988 2,575,972 Sven A. Wehrwein 40,080,389 2,078,609 55,339 2,575,972 Robert S. White 40,893,534 1,265,449 55,354 2,575,972 Maggie Yuen 41,565,558 593,708 55,071 2,575,972”
AtriCure, Inc. shareholders approved Election of Shlomo Nachman as director at the 2024-05-14 meeting.
“Each nominee for director was duty elected to serve one-year terms expiring at the 2025 Annual Meeting of Stockholders and until their successors have been duly elected and qualified. Director Nominees For Against Abstain Broker Non-Votes Michael H. Carrel 41,522,276 637,966 54,095 2,575,972 Regina E. Groves 41,564,382 594,967 54,988 2,575,972 B. Kristine Johnson 40,322,588 1,836,733 55,016 2,575,972 Shlomo Nachman 41,948,710 209,253 56,374 2,575,972 Karen N. Prange 40,301,694 1,857,627 55,016 2,575,972 Deborah H. Telman 40,249,839 1,909,510 54,988 2,575,972 Sven A. Wehrwein 40,080,389 2,078,609 55,339 2,575,972 Robert S. White 40,893,534 1,265,449 55,354 2,575,972 Maggie Yuen 41,565,558 593,708 55,071 2,575,972”
AtriCure, Inc. shareholders approved Election of B. Kristine Johnson as director at the 2024-05-14 meeting.
“Each nominee for director was duty elected to serve one-year terms expiring at the 2025 Annual Meeting of Stockholders and until their successors have been duly elected and qualified. Director Nominees For Against Abstain Broker Non-Votes Michael H. Carrel 41,522,276 637,966 54,095 2,575,972 Regina E. Groves 41,564,382 594,967 54,988 2,575,972 B. Kristine Johnson 40,322,588 1,836,733 55,016 2,575,972 Shlomo Nachman 41,948,710 209,253 56,374 2,575,972 Karen N. Prange 40,301,694 1,857,627 55,016 2,575,972 Deborah H. Telman 40,249,839 1,909,510 54,988 2,575,972 Sven A. Wehrwein 40,080,389 2,078,609 55,339 2,575,972 Robert S. White 40,893,534 1,265,449 55,354 2,575,972 Maggie Yuen 41,565,558 593,708 55,071 2,575,972”
AtriCure, Inc. shareholders approved Election of Regina E. Groves as director at the 2024-05-14 meeting.
“Each nominee for director was duty elected to serve one-year terms expiring at the 2025 Annual Meeting of Stockholders and until their successors have been duly elected and qualified. Director Nominees For Against Abstain Broker Non-Votes Michael H. Carrel 41,522,276 637,966 54,095 2,575,972 Regina E. Groves 41,564,382 594,967 54,988 2,575,972 B. Kristine Johnson 40,322,588 1,836,733 55,016 2,575,972 Shlomo Nachman 41,948,710 209,253 56,374 2,575,972 Karen N. Prange 40,301,694 1,857,627 55,016 2,575,972 Deborah H. Telman 40,249,839 1,909,510 54,988 2,575,972 Sven A. Wehrwein 40,080,389 2,078,609 55,339 2,575,972 Robert S. White 40,893,534 1,265,449 55,354 2,575,972 Maggie Yuen 41,565,558 593,708 55,071 2,575,972”
AtriCure, Inc. shareholders approved Election of Michael H. Carrel as director at the 2024-05-14 meeting.
“Each nominee for director was duty elected to serve one-year terms expiring at the 2025 Annual Meeting of Stockholders and until their successors have been duly elected and qualified. Director Nominees For Against Abstain Broker Non-Votes Michael H. Carrel 41,522,276 637,966 54,095 2,575,972 Regina E. Groves 41,564,382 594,967 54,988 2,575,972 B. Kristine Johnson 40,322,588 1,836,733 55,016 2,575,972 Shlomo Nachman 41,948,710 209,253 56,374 2,575,972 Karen N. Prange 40,301,694 1,857,627 55,016 2,575,972 Deborah H. Telman 40,249,839 1,909,510 54,988 2,575,972 Sven A. Wehrwein 40,080,389 2,078,609 55,339 2,575,972 Robert S. White 40,893,534 1,265,449 55,354 2,575,972 Maggie Yuen 41,565,558 593,708 55,071 2,575,972”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.